COMP <GO>
RMD vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
ResMed Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RMD 6
— MRK 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RMD
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
balance-sheet
12.49
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 74.80% | -15.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 20.70% | +2.20 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.9x | 15.3x | +4.60 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 3.42% | +1.25 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 34.30% | -1.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 28.10% | -0.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 1.30% | +8.50 | RMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 2.26% | -1.39 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.49 | 5.19 | +7.30 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 56.9 | -15.10 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.92 | +0.01 | RMD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 18.4x | +5.20 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $361.02B | -$325.46B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | MRK REV | RMD GROSS % | MRK GROSS % | RMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $65.01B | 59.4% | 74.8% | $1.66B | $12.36B |
| FY 2024 | $4.69B | $64.17B | 56.7% | 76.3% | $1.30B | $18.10B |
| FY 2023 | $4.22B | $60.12B | 44.0% | 44.0% | $503.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
MRK // BETA 0.92